Return to Article Details END-OF-LIFE CARE IN SICKLE CELL DISEASE AND TRANSFUSION-DEPENDENT β-THALASSEMIA: CLINICAL, PSYCHOLOGICAL, AND ETHICAL CONSIDERATIONS